Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients

Arne Schäfer1, Michael Scheurlen, Marc Felten

  • 1Medizinische Klinik und Poliklinik II, Würzburg University, Department of Gastroenterology and Hepatology, Germany. arne.schaefer@mail.uni-wuerzburg.de

Insights

Understanding hepatitis C virus (HCV) disclosure is key to improving patient-doctor relationships. Many patients plan to disclose their HCV status in future appointments, but proactive physician inquiry is crucial for open communication.

Area of Science:

  • Hepatology
  • Psychology
  • Public Health

Background:

  • The doctor-patient relationship in chronic hepatitis C (HCV) infection faces unique challenges.
  • Systematic investigation of factors influencing HCV status disclosure and the doctor-patient relationship is lacking.

Purpose of the Study:

  • To examine hepatitis C virus (HCV) positivity self-disclosure patterns.
  • To assess perceived stigmatization among HCV outpatients.
  • To identify potential predictor variables for HCV disclosure in a German outpatient setting.

Main Methods:

  • Cross-sectional, single-centre study of 103 HCV outpatients.
  • Data collected via standardized face-to-face interviews and psychometric questionnaires.
  • Assessed HCV disclosure behavior, stigmatization, doctor-patient relationship, anxiety, depression, and interpersonal problems.

Main Results:

  • Overall physician disclosure rate was 44.7%, but 75% intended to disclose in future appointments.
  • Disclosure rates were significantly higher with family/friends (e.g., 99% with partners).
  • Sociodemographic factors, personality traits, anxiety, and depression scores did not predict HCV disclosure; stigmatization was higher in women and depressed patients.

Conclusions:

  • Educational interventions are needed to enhance the physician-patient relationship in chronic hepatitis C care.
  • Improved communication can increase HCV disclosure rates and reduce problematic patient contacts.
  • Physicians should proactively inquire about HCV status, as disclosure is not guaranteed.
Abstract

Related Concept Videos

Nursing Ethical Principles II01:27

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Ethical Standards II01:23

Ethical Standards II

Ethical standards are the backbone of nursing practice, guiding nurses as they interact with patients, families, and colleagues. These standards are crucial for providing safe, empathetic care centered on the patient's needs.
Nurses are entrusted with upholding various ethical principles and standards. Nurses forge solid therapeutic relationships using trust, empathy, autonomy, confidentiality, and professional competence.
Confidentiality is crucial, embodying respect for individual privacy and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...